Gene · 56852
RAD18: RAD18 E3 ubiquitin protein ligase
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. RAD18: RAD18 E3 ubiquitin protein ligase. Genes, record 56852. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/56852
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q9NS91 | E3 ubiquitin-protein ligase RAD18 | 495 | 8 | Ensembl, GeneID, HGNC |
Source UniProt
Patents25
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4650780 A2 | 2025-11-19 | 2414 | Q9NS91 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 1993 | Q9NS91 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 1993 | Q9NS91 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 2414 | Q9NS91 | Espacenet |
| EP 4524569 A2 | 2025-03-19 | 30 | Q9NS91 | Espacenet |
| JP 2024123008 A | 2024-09-10 | 7999 | Q9NS91 | Espacenet |
| US 12023339 B2 | 2024-07-02 | 30 | Q9NS91 | Espacenet |
| US 11976334 B2 | 2024-05-07 | 191 | Q9NS91 | Espacenet |
| US 11591295 B2 | 2023-02-28 | 30 | Q9NS91 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 71037 | Q9NS91 | Espacenet |
1 to 10 of 25
See all 25 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants943
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | RAD18 papers | Newest fiscal year |
|---|---|---|---|
| P30ES010126 | UNC Center for Environmental Health and Susceptibility | 21 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 10 | 2025 |
| P30CA016086 | Cancer Center Support Grant | 8 | 2025 |
| P01CA092584 | Structural Cell Biology of DNA Repair Machines | 7 | 2025 |
| R01ES016486 | Regulation of the DNA Damage Response | 7 | 2025 |
| R01CA198279 | Shaping DNA Damage Response Networks Via Histone H2A Variants | 6 | 2025 |
| R01CA248526 | Mechanisms of replication fork protection and recovery | 6 | 2025 |
| R01ES026184 | The Role of Mono-ADP-Ribosylation by PARP14 in Radioresistance | 6 | 2025 |
| R01GM134681 | The role of DNA damage tolerance pathways in human cells | 6 | 2025 |
| ZIAHD001500 | DNA Replication, Repair, and Mutagenesis In Eukaryotic And Prokaryotic Cells | 6 | 2025 |
1 to 10 of 943Source NIH's project files
See all 943 nih grantsPapers1,350
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| A novel mechanism of ubiquitin-charging a bivalent E2:RING E3 complex. | bioRxiv | 2026 | 42818655 | PubTator, text mining | PubMed |
| Overlapping RAD18-and DNA-binding interfaces in DNA polymerase η contribute to UV-induced DNA damage tolerance. | J Biol Chem | 2026 | 42744252 | PubTator, text mining | PubMed |
| Progress for RAD18's mechanism in breast cancer radioresistant. | Open Life Sci | 2026 | 42713304 | PubTator, text mining | PubMed |
| The Oligomeric State of Rad6-Rad18 and Its Interactions with Translesion Synthesis Proteins. | Biomolecules | 2026 | 42650838 | PubTator, text mining | PubMed |
| Neuroinflammation- molecular target based therapeutic approach. | Adv Protein Chem Struct Biol | 2026 | 42448410 | PubTator, text mining | PubMed |
| The miR-221-5p/RAD18/RAD51 Axis Regulates DNA Damage Tolerance and Homologous Recombination to Drive Platinum Resistance in Ovarian Cancer. | bioRxiv | 2026 | 42182447 | PubTator, text mining | PubMed |
| USP1 inhibition promotes RAD18-dependent PCNA degradation and BRCA1 synthetic lethality. | bioRxiv | 2026 | 42146504 | PubTator, text mining | PubMed |
| Coupling of translesion synthesis with the replisome stabilized at stalled replication forks by ATR. | Genes Dev | 2026 | 42140672 | PubTator, text mining | PubMed |
| RAD18 facilitates cancer progression and immunosuppression via the AKT/mTOR/c-Myc axis: a multi-omics analysis. | NPJ Precis Oncol | 2026 | 42115304 | PubTator, text mining | PubMed |
| Novel HBx-interacting host cellular factors regulate dynamic nuclear and cytoplasmic localization of Hepatitis B virus X protein (HBx). | Virology | 2026 | 42105427 | PubTator, text mining | PubMed |
1 to 10 of 1,350
See all 1,350 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/56852
GET https://conductscience.org/api/genes/v1/56852/patents?page=2